Mar 14,2024

Deep learning model ‘detects 90% of lymphatic cancer cases’

Researchers have developed an artificial intelligence algorithm to assist in the diagnosis of lymph node cancer from medical images that has an accuracy of around 90%. The team carried out a retrospective study on the deep learning model, using PET-CT scans from more than 5,000 patients treated for lymphoma at Memorial Sloan Kettering Cancer Center in the US and the Medical University of Vienna in Austria. The Lymphoma Artificial Reader System (LARS) algorithm was trained on 80% of the images, and tested for accuracy on the remaining 20%, comparing the results with the patient’s final diagnosis, according to a paper published in The Lancet Digital Health. The study is thought to be the largest ever to apply deep learning to PET-CT scans and showed a balanced accuracy in detecting whether or not an image had a lymphoma of 87% to 91%. There was also remarkable consistency in the results, despite the use of different equipment and scan procedures by the US and Austrian clinical teams, according to the authors.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 06,2024

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Cognito Therapeutics has published the results of its OVERTURE study in Frontiers in Neurology, highlighting the effects of its Spectris therapy for Alzheimer's disease (AD). The study, conducted over six months with participants having mild to moderate AD, found that Spectris treatment was safe and well-tolerated, with no serious adverse events reported. Efficacy results showed significant slowing in functional decline, cognitive decline, and brain atrophy compared to the sham group. Participants were randomly assigned 2:1 to receive self-administered daily, one-hour Spectris therapy designed to evoke EEG-verified gamma oscillations or sham treatment. Study efficacy results observed include 77% slowing in functional decline, as measured by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) total score, as compared to the sham group.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 11,2024

Cognito Therapeutics Announces Spectris OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced results from the OVERTURE open label extension (OLE) study presented in an oral session at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson's Disease. The results support for Spectris potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD). The OVERTURE clinical trial evaluated the safety and efficacy of Spectris™ therapy in participants with mild to moderate AD in a six-month randomized, double-blind, sham-controlled trial. 83% of the OVERTURE study patients (44/53) entered a separate 12-month open label extension (OLE) study, which allowed for further evaluation of Spectris’ potential as a disease modifying therapy. Participants who continued Spectris™ treatment throughout 18-months showed the potential for safety and durability of treatment effect. Those who switched from sham to Spectris™ treatment demonstrated a similar rate of decline in ADCS-ADL and whole brain volume (WBV) compared to those receiving continued active treatment from the onset

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 04,2024

AI Reveals Prostate Cancer is Not Just One Disease

Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer which could revolutionise how the disease is diagnosed and treated in the future. A Cancer Research UK-funded study reveals that prostate cancer, which affects one in eight men in their lifetime, includes two different subtypes termed evotypes. The discovery was made by an international team led by the University of Oxford, and the University of Manchester, who applied AI (artificial intelligence) on data from DNA to identify two different subtypes affecting the prostate. The researchers used AI to study changes in the DNA of prostate cancer samples (using whole genome sequencing) from 159 patients. They identified two distinct cancer groups among these patients using an AI technique called neural networks. They went on to integrate all the information to generate an evolutionary tree showing how the two subtypes of prostate cancer develop, ultimately converging into two distinct disease types termed 'evotypes'. Crucially, the team's collaboration with Cancer Research UK (CRUK) aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 22,2024

iTalkBetter App Significantly Improves Speech in Stroke Patients

A UCL-developed app that provides speech therapy for people with the language disorder aphasia has been found to significantly improve their ability to talk: iTalkBetter, developed by the Neurotherapeutics Group at the UCL Queen Square Institute of Neurology, provides users the digital platform to practice over 200 commonly used words, in their own time and without any limits on the amount of therapy they receive. While employing games to maintain engagement, the app’s integrated speech recogniser analyses speech in real time to give the user feedback on whether they have named the displayed item correctly. A new study, published in eClinicalMedicine, found that when used over a six-week period for around 90 minutes per day, iTalkBetter significantly improved patients’ ability to name items by 13% for the 200 commonly used words. Importantly, spontaneous speech was also found to improve. iTalkBetter will soon be rolled out as an app available to all suitable patients to use.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 16,2024

New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC

Lunit, a cancer diagnostics AI provider, reveals a study showcasing their AI-powered biomarker, Lunit SCOPE IO, predicting positive outcomes in Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitors. The technology analyzes H&E stained slides, offering quantitative immune phenotyping and categorizing tumors into Inflamed, Immune Excluded, or Immune Desert phenotypes. In a study on 1,806 Immune Checkpoint Inhibitor-treated patients across 27 tumor types, Lunit SCOPE IO demonstrated predictive power for favorable clinical outcomes, supporting its potential as a valuable tool for personalized immunotherapy strategies.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Feb 26,2024 TOP STORY

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan

Akili announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili’s AKL-T01 (marketed as EndeavorRx® in the United States). The submission for marketing approval in Japan is based on the favorable results of the Phase 3 clinical trial conducted by SHIONOGI in the country. The trial aimed to evaluate the efficacy and safety of SDT-001 in 164 pediatric ADHD patients aged 6 to 17 who received conventional treatments such as environmental adjustments and psychosocial therapies. The SDT-001 group, undergoing approximately 25 minutes of treatment once daily for 6 weeks (1 cycle), demonstrated statistically significant improvements in the change from baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Inattention score compared to the control group (continuing conventional treatments) at the 6-week mark, achieving the primary endpoint of the trial.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Feb 23,2024

AI improves adenoma detection in colonoscopies

An artificial intelligence-powered computer-aided detection (CAD) system developed by Israeli medtech company Magentiq-Eye has been shown to improve detection rates for adenoma - premalignant lesions that can develop into cancer - in a colonoscopy clinical trial. The study of the Magentiq-Colo software, which was approved by the FDA last year, showed that AI-aided colonoscopy improved adenoma detection rates (ADR) by 7% and reduced the adenoma miss rate (AMR) by 17% compared to conventional colonoscopy. It was carried out over a period of 14 months across 10 medical centres in Europe, the US, and Israel, and involved 31 endoscopists and 952 screened and enrolled patients. According to the authors of the study, which is published in The Lancet Digital Health journal, the results support the hypothesis that AI-supported CAD can improve the detection of adenomas that may not be picked up during a regular colonoscopy.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Feb 12,2024 TOP STORY

Sidekick's program improves quality of life in rheumatoid arthritis: a retrospective analysis of real-world data

In 2021, Sidekick Health introduced a 16-week digital support program for individuals with rheumatoid arthritis. This retrospective analysis aimed to assess whether users engaged with the program experienced improvements in quality of life (QoL), specifically focusing on sleep quality, energy levels, and stress. Out of 1541 enrolled users, 635 who engaged with the program after the first week were included in the analysis. Users self-reported their QoL up to four times per week on their phones. Users were categorized into highly-engaged and less-engaged groups based on their in-app activities. Both groups showed significant longitudinal improvements in all QoL outcomes, with highly-engaged users achieving better scores in energy, stress, and sleep compared to less-engaged users. Notably, highly-engaged users not only had better sleep scores but also experienced more substantial improvements over time than less-engaged users.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 08,2024

AppliedVR and Kernel Flow Announce Clinical Results Evaluating How Brain Changes During Virtual Reality Treatment of Chronic Pain

AppliedVR and Kernel announced a joint study measuring the impact of VR pain treatment on the brain. The study, which included a single-blind, sham-controlled design, compared brain activation patterns and physiological metrics before, during, and after VR experiences in people experiencing chronic low back pain (CLBP). The research used AppliedVR's RelieVRx medical device, an eight-week, skills-based program that helps chronic low back pain patients learn self-management skills, combined with Kernel Flow and FlowVR—a TD-fNIRS brain measurement headset customized for use in VR—to measure brain hemodynamic changes associated with pain relief. While participants in the RelieVRx and sham groups both experienced varying levels of pain relief after completing the eight-week treatment, researchers determined that participants in the RelieVRx group experienced enhanced brain activation coherence -- change that previously has been related to reduced pain -- from pre-to-post treatment. Those patients receiving the VR sham control demonstrated a decline in brain coherence. Additionally, those receiving treatment from the RelieVRx device achieved a slower breathing rate as compared to the sham VR group. These results suggest that active RelieVRx treatment can create physiological changes in the body and have an impact on coherent global brain activity.

CLINICAL STUDY

#virtual reality

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY